EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 359 filers reported holding EXELIXIS INC in Q1 2023. The put-call ratio across all filers is 0.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,780 | +10.3% | 401,847 | -3.6% | 0.01% | 0.0% |
| Q2 2023 | $7,963 | +46.3% | 416,785 | +48.6% | 0.01% | +150.0% |
| Q1 2023 | $5,444 | -20.7% | 280,471 | -34.5% | 0.00% | -33.3% |
| Q4 2022 | $6,865 | -99.9% | 427,884 | +25.0% | 0.00% | -50.0% |
| Q3 2022 | $5,369,000 | -59.3% | 342,442 | -46.0% | 0.01% | -25.0% |
| Q2 2022 | $13,195,000 | +386.4% | 633,783 | +429.6% | 0.01% | +300.0% |
| Q1 2022 | $2,713,000 | -2.0% | 119,680 | -21.0% | 0.00% | +100.0% |
| Q4 2021 | $2,768,000 | -25.8% | 151,564 | -14.1% | 0.00% | -50.0% |
| Q3 2021 | $3,732,000 | -53.1% | 176,510 | -59.6% | 0.00% | -50.0% |
| Q2 2021 | $7,954,000 | +68.6% | 436,559 | +109.0% | 0.00% | +33.3% |
| Q1 2021 | $4,717,000 | +397.0% | 208,831 | +341.7% | 0.00% | – |
| Q4 2020 | $949,000 | -66.4% | 47,276 | -59.1% | 0.00% | -100.0% |
| Q3 2020 | $2,823,000 | -30.6% | 115,462 | -32.6% | 0.00% | -66.7% |
| Q2 2020 | $4,069,000 | -75.8% | 171,377 | -82.4% | 0.00% | -76.9% |
| Q1 2020 | $16,802,000 | +94.5% | 975,732 | +99.0% | 0.01% | +160.0% |
| Q4 2019 | $8,640,000 | -8.3% | 490,345 | -8.0% | 0.01% | 0.0% |
| Q3 2019 | $9,422,000 | -1.0% | 532,733 | +19.6% | 0.01% | -16.7% |
| Q2 2019 | $9,520,000 | +151.2% | 445,509 | +179.7% | 0.01% | +100.0% |
| Q1 2019 | $3,790,000 | -53.1% | 159,253 | -61.2% | 0.00% | -50.0% |
| Q4 2018 | $8,078,000 | -9.5% | 410,700 | -18.4% | 0.01% | 0.0% |
| Q3 2018 | $8,923,000 | -29.1% | 503,504 | -13.9% | 0.01% | -45.5% |
| Q2 2018 | $12,587,000 | -2.5% | 584,819 | +0.3% | 0.01% | +10.0% |
| Q1 2018 | $12,912,000 | -7.1% | 582,934 | +27.5% | 0.01% | -9.1% |
| Q4 2017 | $13,894,000 | +52.8% | 457,042 | +21.8% | 0.01% | +10.0% |
| Q3 2017 | $9,090,000 | +29.0% | 375,172 | +31.2% | 0.01% | +42.9% |
| Q2 2017 | $7,045,000 | +126.5% | 286,042 | +99.3% | 0.01% | +75.0% |
| Q1 2017 | $3,110,000 | -15.5% | 143,536 | -41.9% | 0.00% | 0.0% |
| Q4 2016 | $3,681,000 | -13.1% | 246,872 | -25.5% | 0.00% | -20.0% |
| Q3 2016 | $4,237,000 | +105.0% | 331,198 | +25.1% | 0.01% | +66.7% |
| Q2 2016 | $2,067,000 | +64.4% | 264,660 | -15.8% | 0.00% | +50.0% |
| Q1 2016 | $1,257,000 | +39.0% | 314,237 | +73.7% | 0.00% | +100.0% |
| Q4 2015 | $904,000 | -30.7% | 180,911 | -30.7% | 0.00% | 0.0% |
| Q3 2015 | $1,305,000 | +88.0% | 260,913 | +12.6% | 0.00% | – |
| Q2 2015 | $694,000 | -61.3% | 231,783 | -74.1% | 0.00% | -100.0% |
| Q1 2015 | $1,791,000 | +345.5% | 894,649 | +122.9% | 0.00% | – |
| Q4 2014 | $402,000 | +10.4% | 401,314 | +10.0% | 0.00% | – |
| Q3 2014 | $364,000 | -71.7% | 364,861 | -14.9% | 0.00% | -100.0% |
| Q2 2014 | $1,286,000 | -17.5% | 428,584 | -17.5% | 0.00% | 0.0% |
| Q1 2014 | $1,559,000 | +147.9% | 519,471 | +395.8% | 0.00% | – |
| Q4 2013 | $629,000 | +5.4% | 104,771 | -12.2% | 0.00% | – |
| Q3 2013 | $597,000 | +8.0% | 119,300 | -2.1% | 0.00% | – |
| Q2 2013 | $553,000 | – | 121,903 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |